All articles tagged with #retatrutide
A new study shows retatrutide, an experimental triple-hormone weight‑loss jab, delivering about 22% body-weight loss in roughly 48 weeks—outperforming Mounjaro's ~19% over ~17 months; GLP-1 drugs like Wegovy and Ozempic hover around 18% in similar timeframes, while retatrutide remains unapproved by the MHRA in the UK. The analysis draws on 38 trials with more than 25,000 participants.
GLP-1 weight-loss drugs show benefits beyond shedding pounds, including reduced inflammation, potential arthritis relief, and cardiovascular improvements, and may even curb alcohol cravings. However, they carry risks such as vitamin deficiencies, loss of eating enjoyment (hedonia), reduced appetite for food, and muscle/bone loss during weight loss, especially in frail patients. Off-label use in people who are not overweight poses safety concerns. A new triple-agonist drug, retatrutide, may deliver 25–30% weight loss—similar to bariatric surgery—but brings more side effects and is in Phase 3 trials, with potential approval in the coming years. Long-term success depends on continued use with diet/exercise; stopping reverses effects and weight tends to rebound.
Eli Lilly filed six lawsuits to crack down on a growing black‑market for retatrutide, an experimental obesity drug not yet approved by the FDA. The company says online merchants, clinics, compounders and foreign sellers are offering untested versions of retatrutide, which could be fake, impure or mis‑dosed. Lilly has referred more than 200 entities to regulators and flagged over 14,000 listings across 100 countries as it prepares for a potential FDA filing next year.
Eli Lilly has filed lawsuits against six U.S. sellers—including California’s Aesthetic Envy and five Texas companies—for distributing illegal retatrutide copies marketed as research-use only but sold for human use, part of a broader effort after FDA warnings; Lilly says it has identified more than 200 entities and 14,000+ online listings worldwide. Retatrutide is investigational and, in Phase 3, has shown up to about 29% weight loss and targets GLP-1, GIP and glucagon; Lilly plans to seek FDA approval early next year.
Eli Lilly filed six lawsuits against U.S. firms accused of illegally selling unapproved retatrutide, a GLP-1 obesity drug still in Phase 3 trials, targeting compounding pharmacies, medical spas and online sellers marketing unverified products while urging tougher platform and regulatory action, citing FDA warnings and CBP seizure data.
Retatrutide (a.k.a. 'Triple G')—an experimental weight-loss drug from Eli Lilly that mimics GLP-1, GIP, and glucagon—has shown substantially greater weight loss than current medications, with trial results reporting up to about 28% body-weight reduction over 80 weeks and additional A1C improvements. Lilly plans an FDA filing in early 2027, potentially a year-long review. Meanwhile, compassionate-use access has raised questions about eligibility, and a regulatory clash over whether retatrutide is a biologic or a peptide could affect exclusivity and future availability.
Eli Lilly says it will allow more patients to apply for pre-approval access to retatrutide, the unapproved obesity drug, after previously granting access to a single 79‑year‑old patient; the company is reviewing requests from doctors in line with FDA guidance.
Eli Lilly’s retatrutide (GIP/GLP-1/glucagon triple agonist) met primary endpoints in two Phase 3 TRIUMPH trials, delivering about 21–23% weight loss at 80 weeks with the 12 mg dose vs ~3.2% for placebo (TRIUMPH-2: 20.8%; TRIUMPH-3: 22.6%). However, cardiovascular risk reduction was not clearly demonstrated, and GI side effects were common (diarrhea, nausea) with higher discontinuation rates. Lilly plans FDA submission in Q1 2027 and frames retatrutide as potentially applicable to obesity, knee osteoarthritis pain, and sleep apnea, though analysts warn the market could be niche and tolerability may limit use.
Eli Lilly said it will file for retatrutide's approval in Q1 2027 after two positive Phase 3 trials showing substantial weight loss and improved glycemic control in adults with obesity and either Type 2 diabetes or cardiovascular disease; the company needs more time to finalize manufacturing data, and retatrutide—a triple-hormone GLP-1/GIP/glucagon drug—could become a key obesity treatment alongside Zepbound and Foundayo.
A Washington Post feature describes how people are buying the weight-loss peptide retatrutide online, highlighting safety concerns and an unclear regulatory status, making it a popular but not clearly legal or regulated consumer option.
Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.
STAT reports that Eli Lilly and the FDA approved compassionate-use access for retatrutide, an experimental obesity drug, to a 79-year-old man—a move that drew attention from top health officials and highlighted concerns about access to promising therapies before FDA approval.
At ADA 2026, Lilly deepened Triumph-1 data for retatrutide, a triple‑agonist GLP‑1/GIP/GLP‑2 program, showing up to 30% weight loss at 104 weeks with the 12 mg dose and meaningful knee osteoarthritis pain and sleep apnea improvements. In Type 2 diabetes, Transcend-T2D-1 reported substantial A1C reductions (around 1.9% at peak doses) with a high share of patients reaching target A1C levels (≤7%, ≤6.5%, and even <5.7%). Cardiometabolic benefits included sizable reductions in triglycerides, non-HDL cholesterol, systolic BP, and waist circumference. Safety signals included higher rates of urinary issues and dysesthesia, plus some arrhythmias and cardiovascular events in treated patients, though Lilly emphasized these events were relatively few. The data underscore Lilly’s strategy of offering multiple obesity medicines as it aims for broader regulatory approvals and patient options by decade’s end.
Lilly’s obesity drug retatrutide, which previously showed rapid weight loss and diabetes benefits, yielded new safety data at the ADA meeting and in Lancet: in TRANSCEND-T2D-1, 7 of 403 participants on retatrutide had arrhythmias and 3 had major cardiovascular events versus none on placebo, a small event count that experts say is insufficient to draw firm cardiovascular risk conclusions.
Lilly revealed that retatrutide, a once‑weekly GIP/GLP‑1/glucagon triple agonist, produced major weight loss (up to 70.3 lbs, 28.3% at 80 weeks) and strong A1C reductions (up to 2.0%) in Phase 3 TRIUMPH-1 and TRANSCEND-T2D-1, plus meaningful knee osteoarthritis pain and sleep apnea improvements, suggesting potential to treat obesity and its related complications; results were presented at the ADA 86th Scientific Sessions and published in The Lancet.